<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165682</url>
  </required_header>
  <id_info>
    <org_study_id>FDCS</org_study_id>
    <nct_id>NCT03165682</nct_id>
  </id_info>
  <brief_title>Fatigue, Depression, and Cortical Excitability in Systemic Lupus</brief_title>
  <official_title>Fatigue, Depression, and Cortical Excitability Changes in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic lupus erythematosus is a chronic inflammatory autoimmune disease with an unknown&#xD;
      cause and many challenges. Whilst corticosteroids and effective immunosuppressive therapy&#xD;
      have transformed the management of patients with active systemic lupus erythematosus, one of&#xD;
      the major causes of morbidity in Systemic lupus erythematosus patients is chronic,&#xD;
      debilitating fatigue.&#xD;
&#xD;
      Despite frequent occurrence of fatigue in Systemic Lupus Erythematosus, to the best of our&#xD;
      knowledge, no studies have been directly performed to examine fatigue-related changes in&#xD;
      cortical motor function in Systemic lupus erythematosus. In this study, we hypothesized that&#xD;
      Systemic lupus erythematosus patients with fatigue and depression versus Systemic lupus&#xD;
      erythematosus patients without fatigue and depression would present an alteration of motor&#xD;
      cortex excitability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatigue, is a multidimensional phenomenon that affects individuals physically, emotionally,&#xD;
      cognitively, and behaviorally.It affects 80-90% of patients with systemic lupus&#xD;
      erythematosus. It is likely multifactorial and may be caused by disordered sleep, anxiety and&#xD;
      depression, pain, polypharmacy, comorbidities, and possibly disease activity.&#xD;
&#xD;
      Additionally, fatigue is the most prevalent symptom in systemic lupus erythematosus, being&#xD;
      present in up to 90% of patients. Moreover, fatigue has a major impact on the Health-Related&#xD;
      Quality Of Life of Systemic lupus erythematosus patients through its impact on family life,&#xD;
      work, social life, emotional wellbeing, and cognition. Therefore, every effort should be made&#xD;
      to relieve fatigue in this population. Recommendations for the management of fatigue usually&#xD;
      combine pharmacologic and nonpharmacologic interventions; however, no speciÔ¨Åc drugs have&#xD;
      proven useful for treating fatigue in Systemic lupus erythematosus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cortical excitability assessment among studied participants.</measure>
    <time_frame>six months</time_frame>
    <description>Done by Transcranial Magnetic Stimulation :&#xD;
For assessment of cortical excitability parameters (resting and active motor threshold Cortical Silent Period at different intensities) among studied participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression assessment among studied participants.</measure>
    <time_frame>six months</time_frame>
    <description>The Beck Depression Inventory (BDI), self-assessment question, is one of the most widely used instruments to evaluate the severity of depression. The results were evaluated by a psychiatrist.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Twenty-five age, sex and educationally matched controls among the health worker.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        not related&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All the participants:&#xD;
&#xD;
               1. 18 years of age or older.&#xD;
&#xD;
               2. For Systemic lupus patients: have a stable drug regimen for 3 months prior to&#xD;
                  study entry; disease duration for at least 6 months or longer&#xD;
&#xD;
               3. able to give written consent for participation.&#xD;
&#xD;
               4. able to understand and respond the questionnaires.&#xD;
&#xD;
               5. be free of serious comorbid medical conditions such as diabetes, congestive heart&#xD;
                  failure, renal failure, cancer, or fibromyalgia, which would confound&#xD;
                  interpretations of health status; and not pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient will meet any of these conditions will be excluded from the study, that&#xD;
             including:&#xD;
&#xD;
               1. Patient less than 18 years old.&#xD;
&#xD;
               2. Patients with a definite diagnosis of any other systemic autoimmune disorders.&#xD;
&#xD;
               3. History of any other neurologic disease, seizure or major medical disorders&#xD;
                  including heart failure, respiratory compromise, renal insufficiency, hepatic&#xD;
                  dysfunction, diabetes mellitus, malignancy, or endocrinal disturbance.&#xD;
&#xD;
               4. Other contraindications of Transcranial Magnetic Stimulation as:&#xD;
&#xD;
                    1. Personal or family history of epilepsy, brain tumor, brain injury.&#xD;
&#xD;
                    2. History of metallic particles in the eye or head outside the mouth,&#xD;
&#xD;
                    3. Cardiac pacemakers, implanted neurostimulators, cochlear implants, implanted&#xD;
                       medication pumps.&#xD;
&#xD;
                    4. History of drug or alcohol abuse.&#xD;
&#xD;
                    5. Pregnancy.&#xD;
&#xD;
                    6. Comedication with neuroleptics and tricyclic antidepressants (amitriptyline&#xD;
                       etc.)&#xD;
&#xD;
                    7. Patients with increased intracranial pressure (which lowers seizure&#xD;
                       threshold intracardiac line).&#xD;
&#xD;
                    8. Significant heart disease: extensive ischemia.&#xD;
&#xD;
                    9. Bipolar disorder.&#xD;
&#xD;
                   10. History of stroke or other brain lesions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rania M. Gamal-El Din, Assistant Professor Dr</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eman M. El-Hakeem, Lecturer Dr</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eman H. Khedr, Professor Dr.</last_name>
    <phone>00201005850632</phone>
    <email>Emankhedr99@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sounia M. Rashad, Professor Dr.</last_name>
    <phone>00201005451230</phone>
    <email>souniarashad@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. Arthritis Rheum. 2005 Dec;52(12):3701-12. Review.</citation>
    <PMID>16320320</PMID>
  </results_reference>
  <results_reference>
    <citation>McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 2003 Aug;48(8):2100-10. Review.</citation>
    <PMID>12905462</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 20, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mary Jacob Ross</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>fatigue</keyword>
  <keyword>depression</keyword>
  <keyword>cortical excitability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

